Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654836 | 0.88 | CPT2 (0.46) | CPT2CPT1AAKT1AKT2TP53 | |
| SCHEMBL10070549 | 0.85 | KIT (0.44) | HSD11B1AKT1AKT2TP53P2RY12 | |
| SCHEMBL10070083 | 0.84 | P2RY12 (0.40) | CPT1AHSD11B1AKT1AKT2TP53 | |
| SCHEMBL10069718 | 0.84 | CPT1A (0.45) | CPT1AHSD11B1AKT1AKT2P2RY12 | |
| SCHEMBL10069540 | 0.81 | HCRTR1 (0.41) | CPT2CPT1AAKT1AKT2HCRTR1 | |
| SCHEMBL10070098 | 0.81 | CPT2 (0.51) | CPT2CPT1ATP53 | |
| SCHEMBL10070556 | 0.80 | HCRTR1 (0.42) | CPT2CPT1AAKT1AKT2HCRTR1 | |
| SCHEMBL10070107 | 0.80 | AKT1 (0.42) | CPT2CPT1AAKT1AKT2HCRTR1 | |
| SCHEMBL10070512 | 0.79 | HSD11B1 (0.42) | HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL12231359 | 0.79 | CPT1A (0.54) | CPT2CPT1AHSD11B1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | CPT2 2583/4885CPT1A 1233/4885HSD11B1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.